nanotech investing The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
nanotech investing Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
nanotech investing Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
nanotech investing Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
nanotech investing Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
nanotech investing Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells
nanotech investing Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells
nanotech investing Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome
